These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1656852)

  • 1. Mechanisms of clinical resistance to fluoroquinolones in Enterococcus faecalis.
    Nakanishi N; Yoshida S; Wakebe H; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1053-9. PubMed ID: 1656852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of clinical resistance to fluoroquinolones in Staphylococcus aureus.
    Nakanishi N; Yoshida S; Wakebe H; Inoue M; Yamaguchi T; Mitsuhashi S
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2562-7. PubMed ID: 1667255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of moxifloxacin against fluoroquinolone-resistant strains of aerobic gram-negative bacilli and Enterococcus faecalis.
    Tankovic J; Bachoual R; Ouabdesselam S; Boudjadja A; Soussy CJ
    J Antimicrob Chemother; 1999 May; 43 Suppl B():19-23. PubMed ID: 10382871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of fluoroquinolone resistance in Enterococcus faecalis and role of mutations in the DNA gyrase gyrA gene.
    Tankovic J; Mahjoubi F; Courvalin P; Duval J; Leclerco R
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2558-61. PubMed ID: 8913464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of high-level quinolone resistance in Campylobacter jejuni.
    Gootz TD; Martin BA
    Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus.
    Okuda J; Okamoto S; Takahata M; Nishino T
    Antimicrob Agents Chemother; 1991 Nov; 35(11):2288-93. PubMed ID: 1666495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis by PCR and direct DNA sequencing of gyrA mutations associated with fluoroquinolone resistance in Enterococcus faecalis.
    Korten V; Huang WM; Murray BE
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2091-4. PubMed ID: 7811024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase mutations and efflux are associated with fluoroquinolone resistance in Enterococcus faecalis.
    Oyamada Y; Ito H; Inoue M; Yamagishi JI
    J Med Microbiol; 2006 Oct; 55(Pt 10):1395-1401. PubMed ID: 17005789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
    Arsène S; Leclercq R
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3254-8. PubMed ID: 17620379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis.
    Kanematsu E; Deguchi T; Yasuda M; Kawamura T; Nishino Y; Kawada Y
    Antimicrob Agents Chemother; 1998 Feb; 42(2):433-5. PubMed ID: 9527801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of acquired ciprofloxacin resistance in a clinical strain of Pseudomonas aeruginosa.
    Masecar BL; Celesk RA; Robillard NJ
    Antimicrob Agents Chemother; 1990 Feb; 34(2):281-6. PubMed ID: 2158277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones.
    Moreau NJ; Houot S; Joly-Guillou ML; Bergogne-Bérézin E
    J Antimicrob Chemother; 1996 Dec; 38(6):1079-83. PubMed ID: 9023657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutation in DNA gyrase of norfloxacin-resistant clinical isolates of Neisseria gonorrhoeae.
    Tanaka M; Otsuki M; Nishino T; Kobayashi I; Matsumoto T; Kumazawa J
    Genitourin Med; 1996 Aug; 72(4):295-7. PubMed ID: 8976839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients.
    Alangaden GJ; Manavathu EK; Vakulenko SB; Zvonok NM; Lerner SA
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1700-3. PubMed ID: 7486904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.
    Morrissey I; George J
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2579-85. PubMed ID: 10543732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.